| ORIGINAL ARTICLE |
|
| Year : 2011 | Volume
: 59
| Issue : 1 | Page : 13-16 |
|
|
Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: A preliminary study
Prateep Vyas1, Uday Naik1, Jayasheel B Gangaiah2
1 Department of Ophthalmology, Choithram Netralaya, Dhar Road, Indore - 01, India
2 Manipal AcuNova Limited, Mobius Towers, SJR - I Park, EPIP Zone, Whitefield, Bangalore - 560 066, India
Correspondence Address:
Jayasheel B Gangaiah
Manipal AcuNova Limited, Mobius Towers, SJR - I Park, EPIP Zone, Whitefield, Bangalore - 560 066
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0301-4738.73708
|
|
|
Context: Peripheral anterior synechiae (PAS; synechiae anterior to functional trabecular meshwork) formation in primary angle-closure glaucoma (PACG) hampers access to uveoscleral outflow. Thus, the role of bimatoprost in such patients with 360° synechiae was evaluated. Aims: To assess efficacy and safety profile of bimatoprost 0.03% in lowering intraocular pressure (IOP) in 360° synechial angle-closure glaucoma patients. Settings and Design: This was a prospective, non-randomized, non-comparative, selective analysis, single-center pilot study. Materials and Methods: A total of 23 eyes of 20 Indian chronic angle-closure glaucoma (CACG) patients with IOP greater than 21 mmHg, 360° PAS and no visual potential in the study eye underwent detailed eye examination. Baseline IOP was measured and YAG peripheral iridotomy was performed for complete angle-closure reconfirmation. Bimatoprost 0.03% was administered for 8 weeks as once-daily evening dose. IOP reduction within treatment group was determined with "paired t-test." Results: The mean reduction in IOP from baseline to 8 weeks of bimatoprost therapy was 15.3 ± 9.5 mmHg (P < 0.001). The most commonly observed adverse event was conjunctival hyperemia (35%). Bimatoprost was well tolerated in the study. Conclusions: In this study, exclusively involving patients with 360° synechial angle-closure glaucoma and no visual potential, bimatoprost 0.03% treatment demonstrated a statistically significant IOP reduction. Hence, it can be inferred that bimatoprost 0.03% is an efficacious treatment modality in this subgroup of patients for reducing IOP. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
.png "Santen")
